Clinical trials: Refractory Cancer, active
Ovarian Cancer
Identification of Genetic, Phenotypic, Clinical, Biological and Histological Factors Differentiating Patients With Ovarian Cancer Who Are Refractory to Platinum-based Therapy From Patients Defined as Long-term Responders to Platinum-based Therapy
After having constituted the ORTRAI cohort using the CONSORE database at the Jean PERRIN Center, the objective is to characterize the patients both clinically and biologically, histologically and genomically.
- Trial name
- ORTRAI (NCT07361471)
- Testing
- molecular analysis
- Where
- France
- Volunteers
- 55 people
- Sponsor
- Centre Jean Perrin
B Cell Leukemias, B Cell Lymphomas
CD22 Redirected Autologous T Cells for ALL
This is a pilot study to determine the feasibility and safety of a single dose of autologous T cells expressing CD22 chimeric antigen receptors expressing tandem TCR-ζ and 4-1BB signaling domains (CART22/CART22-65s cells) in…
- Trial name
- NCT02650414
- Testing
- Cohort 1, Cohorts 2, Cohort 3
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Pennsylvania
Solid Tumor Cancer, Medulloblastoma
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Study in children and adolescents of 177Lu DOTATATE (Lutathera®) combined with the PARP inhibitor olaparib for treatment of recurrent or relapsed solid tumours expressing somatostatin receptors (SSTR) (LuPARPed)
- Conditions
- Solid Tumor Cancer, Medulloblastoma, High Risk Neuroblastoma, High Grade Gliomas
- Trial name
- LUPARPED (NCT06607692)
- Testing
- Olaparib; 177Lu-DOTATATE
- Where
- Spain
- Volunteers
- 25 people
- Sponsor
- Fundación de investigación HM
Waldenstrom's Macroglobulinemia
Teclistamab In Waldenstrom's Macroglobulinemia
The goal of this clinical trial is to assess the efficacy of teclistamab in participants with relapsed or refractory Waldenstrom's macroglobulinemia who have received prior therapy.
- Trial name
- NCT07791498
- Testing
- Teclistamab
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Massachusetts General Hospital
Hodgkin Lymphoma
A Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab at the Fixed Dose 40 mg, Ifosfamide, Carboplatin, Etoposide (NICE-40) in Patients With Relapsed/Refractory Hodgkin Lymphoma
Nivolumab is an anti-PD-1 antibody highly effective in patients with relapsed/refractory classical Hodgkin lymphoma. A PET-adapted regimen of Nivo combined with ICE as first salvage therapy was shown to induce high response rates…
- Trial name
- NICE-40 (NCT04981899)
- Testing
- Nivolumab, Ifosfamide, Carboplatin
- Where
- 3 sites in Russia
- Volunteers
- 30 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Relapsed or Refractory Multiple Myeloma
A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003
The purpose of this study is to evaluate how well IBI3003 works when compared with the investigator's choice regimen (DPd or PVd or SVd)
- Trial name
- NCT07623798
- Testing
- Pomalidomide Capsules, Bortezomib for Injection, Daratumumab Injection (Subcutaneous Injection)
- Where
- China
- Volunteers
- 255 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Solid Tumor
A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors
This is a Phase I, FIH, open-label, multi-site, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of claudin 6 (CLDN6) chimeric antigen receptor T cells (CAR-T) with or without CLDN6…
- Trial name
- NCT04503278
- Testing
- CLDN6 CAR-T, CLDN6 uRNA-LPX/CLDN6 modRNA-LPX
- Where
- 12 sites in Australia, Germany and 2 more
- Volunteers
- 214 people
- Sponsor
- BioNTech Cell & Gene Therapies GmbH
Relapsed or Refractory Multiple Myeloma
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory…
- Trial name
- SUCCESSOR-1 (NCT05519085)
- Testing
- mezigdomide, Pomalidomide, Bortezomib
- Where
- 266 sites in United States, Argentina and 27 more
- Volunteers
- 810 people
- Sponsor
- Celgene
Bladder Cancer
A Study of IAP0971 in Combination With Bacillus Calmette Guerin in High Risk Non-muscular Invasive Bladder Cancer
The efficacy and safety of IAP0971 single drug or combined with BCG intravesical instillation in the treatment of high-risk non muscle invasive bladder cancer with BCG treatment failure.
- Trial name
- NCT06255964
- Testing
- IAP0971, IAP0971＋BCG
- Volunteers
- 236 people
- Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
Relapsed and Refractory Multiple Myeloma
Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
The purpose of this research is to determine whether the combination of selinexor, venetoclax, and dexamethasone therapy can increase anti-cancer effects in patients with translocation 11;14-positive (t(11;14))…
- Trial name
- SELVEDge (NCT05530421)
- Testing
- Selinexor, Venetoclax, Dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- University of Miami
Multiple Myeloma
A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation
The purpose of this study is to test any good and bad effects of giving a combination of study drugs before and after autologous stem cell transplant.
- Trial name
- NCT03556332
- Testing
- Carfilzomib, Lenalidomide, Dexamethasone
- Where
- 12 sites in United States
- Volunteers
- 41 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Follicular Lymphoma
Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study
This study is planned to prospectively observe and verify the efficacy and safety of induction therapy with obinutuzumab in combination with lenalidomide followed by maintenance therapy with obinutuzumab and lenalidomide in…
- Trial name
- NCT05846763
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Advanced Malignant Solid Neoplasm, RAS Mutation
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed…
- Conditions
- Advanced Malignant Solid Neoplasm, RAS Mutation, Lung Cancer, Colon Cancer
- Trial name
- NCT04678648
- Testing
- RSC-1255 Dose Escalation, RSC-1255 Dose Expansion
- Where
- 3 sites in United States
- Volunteers
- 134 people
- Sponsor
- RasCal Therapeutics, Inc.
Advanced Solid Tumors, Acute Myeloid Leukaemia (AML)
RVU120 Rollover Study
This is a multicenter rollover study to provide continued treatment to eligible participants previously enrolled in a RVU120 clinical study and to evaluate the safety of the treatment and record the time on treatment when…
- Conditions
- Advanced Solid Tumors, Acute Myeloid Leukaemia (AML), High-risk Myelodysplastic Syndrome
- Trial name
- ROVER-01 (NCT06987058)
- Testing
- RVU120, Ruxolitinib
- Where
- 7 sites in France, Poland
- Volunteers
- 14 people
- Sponsor
- Ryvu Therapeutics SA
Nasopharyngeal Carcinoma
Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma
This study was a single-arm, open-label, "3 + 3" dose-escalation Exploratory research. The patients were divided into two groups: EBV TCR-T-cell Group and EBV CAR-T-cell group.
- Trial name
- NCT05587543
- Testing
- PK Blood Collection, CAR, TCR
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Fudan University
Hematologic Diseases, Neoplasms
CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases
This is a single-arm, open-label, single-center, phase I/II study. The primary objective is to evaluate the safety of CD7 CAR-T Bridging to allo-HSCT therapy for patients with CD7-positive relapsed or refractory Malignant…
- Trial name
- NCT05827835
- Testing
- CD7 CAR-T cells injection, Allogeneic hematopoietic stem cell transplantation
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang University
Non-muscle Invasive Bladder Cancer
A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer
The purpose of this study is to learn about the safety and effects of the study medicine (sasanlimab) in people with non-muscle invasive bladder cancer.
- Trial name
- CREST (NCT04165317)
- Testing
- PF-06801591, Bacillus Calmette-Guerin
- Where
- 196 sites in United States, Australia and 12 more
- Volunteers
- 1,068 people
- Sponsor
- Pfizer
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma
MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
This phase I trial tests the safety, side effects, best dose of MUC1-activated T cells in treating patients with ovarian cancer that has come back after a period of improvement (relapsed) or that remains despite treatment…
- Conditions
- Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT06483048
- Testing
- Autologous MUC1-activated T-cells, Bendamustine, Biospecimen Collection
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Mayo Clinic
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia
Non-commercial, open-label interventional phase Ib study to assess the effectivity of the combination of venetoclax and 6-mercaptopurine in patients with relapsed or refractory AML.
- Trial name
- NCT05506332
- Testing
- Venetoclax, 6-mercaptopurine
- Where
- 2 sites in Belgium
- Volunteers
- 10 people
- Sponsor
- University Hospital, Antwerp
Multiple Myeloma
Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
This is a Phase 3, randomized, open-label study designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone (Arm A) versus daratumumab in combination with bortezomib/dexamethasone…
- Trial name
- DREAMM 7 (NCT04246047)
- Testing
- Belantamab mafodotin, Daratumumab, Bortezomib
- Where
- 69 sites in United States, Australia and 11 more
- Volunteers
- 494 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.